Literature DB >> 19961025

Effects of heated humidification and topical steroids on compliance, nasal symptoms, and quality of life in patients with obstructive sleep apnea syndrome using nasal continuous positive airway pressure.

Silke Ryan1, Liam S Doherty, Geraldine M Nolan, Walter T McNicholas.   

Abstract

BACKGROUND: Nasal side effects are common in patients with obstructive sleep apnea syndrome (OSAS) starting on nasal continuous positive airway pressure (CPAP) therapy. We tested the hypothesis that heated humidification or nasal topical steroids improve compliance, nasal side effects and quality of life in this patient group.
METHODS: 125 patients with the established diagnosis of OSAS (apnea/hypopnea index > or = 10/h), who tolerated CPAP via a nasal mask, and who had a successful CPAP titration were randomized to 4 weeks of dry CPAP, humidified CPAP or CPAP with additional topical nasal steroid application (fluticasone, GlaxoWellcome). Groups were similar in all demographic variables and in frequency of nasal symptoms at baseline. Outcome measures were objective compliance, quality of life (short form 36), subjective sleepiness (Epworth Sleepiness Scale score) and nasal symptoms such as runny, dry or blocked nose, sneezing and headaches; all variables assessed using a validated questionnaire and by direct interview.
RESULTS: There was no difference in compliance between groups after 4 weeks (dry: 5.21 +/- 1.66 h/night, fluticasone: 5.66 +/- 1.68, humidifier: 5.21 +/- 1.84; p = 0.444). Quality of life and subjective sleepiness improved in all groups, but there were no differences in the extent of improvement. Nasal Symptoms were less frequently reported in the humidifier group (28%) than in the remaining groups (dry: 70%, fluticasone: 53%, p = 0.002). However, the addition of fluticasone resulted in increased frequency of sneezing.
CONCLUSION: The addition of a humidifier, but not nasal steroids decreases the frequency of nasal symptoms in unselected OSAS patients initiating CPAP therapy; however compliance and quality of life remain unaltered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19961025      PMCID: PMC2762712     

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  30 in total

Review 1.  Epidemiology of obstructive sleep apnea: a population health perspective.

Authors:  Terry Young; Paul E Peppard; Daniel J Gottlieb
Journal:  Am J Respir Crit Care Med       Date:  2002-05-01       Impact factor: 21.405

2.  Efficiency of cold passover and heated humidification under continuous positive airway pressure.

Authors:  W J Randerath; J Meier; H Genger; U Domanski; K H Rühle
Journal:  Eur Respir J       Date:  2002-07       Impact factor: 16.671

3.  Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study.

Authors:  F J Nieto; T B Young; B K Lind; E Shahar; J M Samet; S Redline; R B D'Agostino; A B Newman; M D Lebowitz; T G Pickering
Journal:  JAMA       Date:  2000-04-12       Impact factor: 56.272

4.  Nasal obstruction as a risk factor for sleep apnoea syndrome.

Authors:  F Lofaso; A Coste; M P d'Ortho; F Zerah-Lancner; C Delclaux; F Goldenberg; A Harf
Journal:  Eur Respir J       Date:  2000-10       Impact factor: 16.671

5.  Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study.

Authors:  E Shahar; C W Whitney; S Redline; E T Lee; A B Newman; F J Nieto; G T O'Connor; L L Boland; J E Schwartz; J M Samet
Journal:  Am J Respir Crit Care Med       Date:  2001-01       Impact factor: 21.405

6.  Effectiveness of CPAP treatment in daytime function in sleep apnea syndrome: a randomized controlled study with an optimized placebo.

Authors:  J M Montserrat; M Ferrer; L Hernandez; R Farré; G Vilagut; D Navajas; J R Badia; E Carrasco; J De Pablo; E Ballester
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

7.  Continuous positive airway pressure for sleep apnoea/hypopnoea syndrome: usefulness of a 2 week trial to identify factors associated with long term use.

Authors:  G Popescu; M Latham; V Allgar; M W Elliott
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

8.  Predictive factors for the need for additional humidification during nasal continuous positive airway pressure therapy.

Authors:  D Rakotonanahary; N Pelletier-Fleury; F Gagnadoux; B Fleury
Journal:  Chest       Date:  2001-02       Impact factor: 9.410

9.  Nasal cytology: a marker of clinically silent inflammation in patients with obstructive sleep apnea and a predictor of noncompliance with nasal CPAP therapy.

Authors:  Farhad F Shadan; Alfredo A Jalowayski; John Fahrenholz; Lawrence E Kline; Arthur Dawson
Journal:  J Clin Sleep Med       Date:  2005-07-15       Impact factor: 4.062

Review 10.  Adherence to continuous positive airway pressure therapy: the challenge to effective treatment.

Authors:  Terri E Weaver; Ronald R Grunstein
Journal:  Proc Am Thorac Soc       Date:  2008-02-15
View more
  23 in total

1.  The quest to improve CPAP adherence--PAP potpourri is not the answer.

Authors:  Stuart F Quan; Karim M Awad; Rohit Budhiraja; Sairam Parthasarathy
Journal:  J Clin Sleep Med       Date:  2012-02-15       Impact factor: 4.062

Review 2.  The effects of topical nasal steroids on continuous positive airway pressure compliance in patients with obstructive sleep apnea: a systematic review and meta-analysis.

Authors:  Natamon Charakorn; Prakobkiat Hirunwiwatkul; Naricha Chirakalwasan; Busarakum Chaitusaney; Mantana Prakassajjatham
Journal:  Sleep Breath       Date:  2016-07-08       Impact factor: 2.816

Review 3.  Clinical review: humidifiers during non-invasive ventilation--key topics and practical implications.

Authors:  Antonio M Esquinas Rodriguez; Raffaele Scala; Arie Soroksky; Ahmed BaHammam; Alan de Klerk; Arschang Valipour; Davide Chiumello; Claude Martin; Anne E Holland
Journal:  Crit Care       Date:  2012-02-08       Impact factor: 9.097

4.  Effect of APAP and heated humidification with a heated breathing tube on adherence, quality of life, and nasopharyngeal complaints.

Authors:  Georg Nilius; Karl J Franke; Ulrike Domanski; Maik Schroeder; Karl H Ruhle
Journal:  Sleep Breath       Date:  2015-05-10       Impact factor: 2.816

5.  Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment.

Authors:  Susheel P Patil; Indu A Ayappa; Sean M Caples; R Joh Kimoff; Sanjay R Patel; Christopher G Harrod
Journal:  J Clin Sleep Med       Date:  2019-02-15       Impact factor: 4.062

6.  Randomised short-term trial of high-span versus low-span APAP for treating sleep apnoea.

Authors:  Helder Novais Bastos; Ana Verónica Cardoso; Ana Sofia Castro; Rita Gomes; Tiago Pinto; Anabela Marinho; Maria Sucena; João Almeida; Marta Drummond; João Carlos Winck
Journal:  Sleep Breath       Date:  2015-06-12       Impact factor: 2.816

7.  Adherence to CPAP therapy improves quality of life and reduces symptoms among obstructive sleep apnea syndrome patients.

Authors:  Eirini Avlonitou; Fotis Kapsimalis; George Varouchakis; Constantine I Vardavas; Panagiotis Behrakis
Journal:  Sleep Breath       Date:  2011-06-11       Impact factor: 2.816

Review 8.  When continuous positive airway pressure (CPAP) fails.

Authors:  Jagdeep S Virk; Bhik Kotecha
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

9.  Treatment of obstructive sleep apnea syndrome with nasal positive airway pressure improves golf performance.

Authors:  Marc L Benton; Neil S Friedman
Journal:  J Clin Sleep Med       Date:  2013-12-15       Impact factor: 4.062

10.  The influence of nasal abnormalities in adherence to continuous positive airway pressure device therapy in obstructive sleep apnea patients.

Authors:  Fernanda Louise Martinho Haddad; Tatiana de Aguiar Vidigal; Luciane Mello-Fujita; Fátima Dumas Cintra; Luiz Carlos Gregório; Sérgio Tufik; Lia Bittencourt
Journal:  Sleep Breath       Date:  2013-03-06       Impact factor: 2.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.